A time to kill: Targeting apoptosis in cancer

International Journal of Molecular Sciences

Volumn 16, Issue 2, 2015, Pages 2942-2955

  Koff, Jean L ^a   Ramachandiran, Sampath ^a   Bernal Mizrachi, Leon ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Cancer; Targeting apoptosis

Indexed keywords

CASPASE; DEATH RECEPTOR; FAS ANTIGEN; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; TUMOR NECROSIS FACTOR;

APOPTOSIS; AUTOPHAGY; CANCER THERAPY; CELL DEATH; CELL GROWTH; CELL PERMEABILIZATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA DAMAGE; DNA FRAGMENTATION; EXTRINSIC PATHWAY; HUMAN; INTRINSIC PATHWAY; LYSOSOME; MITOCHONDRION; NEOPLASM; PATHWAY REGULATION; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; NEOPLASMS; PATHOLOGY;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASES; HUMANS; NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922022634     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16022942     Document Type: Review

References (70)

1. Tomei, L.D.; Cope, F.O. Apoptosis: The Molecular Basis of Cell Death; Books on Demand: Stoughton, WI, USA, 1991.
2. Kroemer, G.; Galluzzi, L.; Vandenabeele, P.; Abrams, J.; Alnemri, E.S.; Baehrecke, E.H.; Blagosklonny, M.V.; El-Deiry, W.S.; Golstein, P.; Green, D.R.; et al. Classification of cell death: Recommendations of the Nomenclature Committee on Cell Death 2009. Cell. Death Differ. 2008, 16, 3-11.
3. Robbins, S.L.; Kumar, V.; Abbas, A.K.; Cotran, R.S.; Fausto, N. Robbins and Cotran's Pathologic Basis of Disease; Elsevier Health Sciences: Makati City, Philippines, 2009.
4. Parrish, A.B.; Freel, C.D.; Kornbluth, S. Cellular mechanisms controlling caspase activation and function. Cold Spring Harb. Perspect. Biol. 2013, 5, doi:10.1101/cshperspect.a008672.
5. Lin, Y.; Devin, A.; Rodriguez, Y.; Liu, Z.-G. Cleavage of the death domain kinase RIP by Caspase-8 prompts TNF-induced apoptosis. Genes Dev. 1999, 13, 2514-2526.
6. Zhang, D.-W.; Shao, J.; Lin, J.; Zhang, N.; Lu, B.-J.; Lin, S.-C.; Dong, M.-Q.; Han, J. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009, 325, 332-336.
7. Long, J.S.; Ryan, K.M. New frontiers in promoting tumour cell death: Targeting apoptosis, necroptosis and autophagy. Oncogene 2012, 31, 5045-5060.
8. Wertz, I.E.; Dixit, V.M. Regulation of death receptor signaling by the ubiquitin system. Cell Death Differ. 2009, 17, 14-24.
9. Gyrd-Hansen, M.; Meier, P. IAPs: From caspase inhibitors to modulators of NF-κB, inflammation and cancer. Nat. Rev. Cancer 2010, 10, 561-574.
10. Dewson, G.; Kratina, T.; Czabotar, P.; Day, C.L.; Adams, J.M.; Kluck, R.M. Bak activation for apoptosis involves oligomerization of dimers via their alpha6 helices. Mol. Cell. 2009, 36, 696-703.
11. Goldstein, J.C.; Waterhouse, N.J.; Juin, P.; Evan, G.I.; Green, D.R. The coordinate release of cytochrome C during apoptosis is rapid, complete and kinetically invariant. Nat. Cell. Biol. 2000, 2, 156-162.
12. Wei, M.C.; Zong, W.-X.; Cheng, E.H.-Y.; Lindsten, T.; Panoutsakopoulou, V.; Ross, A.J.; Roth, K.A.; MacGregor, G.R.; Thompson, C.B.; Korsmeyer, S.J. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 2001, 292, 727-730.
13. Cory, S.; Adams, J.M. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2002, 2, 647-656.
14. Bratton, S.B.; Salvesen, G.S. Regulation of the Apaf-1-caspase-9 apoptosome. J. Cell Sci. 2010, 123, 3209-3214.
15. Tait, S.W.G.; Green, D.R. Mitochondrial Regulation of Cell Death. Cold Spring Harb. Perspect. Biol. 2013, 5, doi:10.1101/cshperspect.a008672.
16. Youle, R.J.; Strasser, A. The BCL-2 protein family: Opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 2008, 9, 47-59.
17. LaCasse, E.C.; Mahoney, D.J.; Cheung, H.H.; Plenchette, S.; Baird, S.; Korneluk, R.G. IAP-targeted therapies for cancer. Oncogene 2008, 27, 6252-6275.
18. Silke, J.; Meier, P. Inhibitor of apoptosis (IAP) proteins-Modulators of cell death and inflammation. Cold Spring Harb. Perspect. Biol. 2013, 5, doi:10.1101/cshperspect.a008730.
19. Estornes, Y.; Bertrand, M.J.M. IAPs, regulators of innate immunity and inflammation. Semin. Cell Dev. Biol. 2014, doi:10.1016/j.semcdb.2014.03.035
20. Chen, D.J.; Huerta, S. Smac mimetics as new cancer therapeutics. Anticancer Drugs 2009, 20, 646-658.
21. Okada, H.; Suh, W.-K.; Jin, J.; Woo, M.; Du, C.; Elia, A.; Duncan, G.S.; Wakeham, A.; Itie, A.; Lowe, S.W.; et al. Generation and characterization of smac/DIABLO-deficient mice. Mol. Cell. Biol. 2002, 22, 3509-3517.
22. Jones, J.M.; Datta, P.; Srinivasula, S.M.; Ji, W.; Gupta, S.; Zhang, Z.; Davies, E.; Hajnoczky, G.; Saunders, T.L.; van Keuren, M.L.; et al. Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of MND2 mutant mice. Nature 2003, 425, 721-727.
23. Martins, L.M.; Morrison, A.; Klupsch, K.; Fedele, V.; Moisoi, N.; Teismann, P.; Abuin, A.; Grau, E.; Geppert, M.; Livi, G.P.; et al. Neuroprotective role of the reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol. Cell. Biol. 2004, 24, 9848-9862.
24. Zhuang, M.; Guan, S.; Wang, H.; Burlingame Alma, L.; Wells James, A. Substrates of IAP ubiquitin ligases identified with a designed orthogonal E3 ligase, the NEDDylator. Mol. Cell 2013, 49, 273-282.
25. Maiuri, M.C.; le Toumelin, G.; Criollo, A.; Rain, J.C.; Gautier, F.; Juin, P.; Tasdemir, E.; Pierron, G.; Troulinaki, K.; Tavernarakis, N.; et al. Functional and physical interaction between Bcl-XL and a BH3-like domain in beclin-1. 2007, 26, 1527-2539.
26. Yousefi, S.; Perozzo, R.; Schmid, I.; Ziemiecki, A.; Schaffner, T.; Scapozza, L.; Brunner, T.; Simon, H.-U. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat. Cell. Biol. 2006, 8, 1124-1132.
27. Foghsgaard, L.; Wissing, D.; Mauch, D.; Lademann, U.; Bastholm, L.; Boes, M.; Elling, F.; Leist, M.; Jäättelä, M. Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J. Cell Biol. 2001, 153, 999-1010.
28. Appelqvist, H.; Wäster, P.; Kågedal, K.; Öllinger, K. The lysosome: from waste bag to potential therapeutic target. J. Mol. Cell Biol. 2013, 5, 214-226.
29. Johansson, A.-C.; Appelqvist, H.; Nilsrighson, C.; Kågedal, K.; Roberg, K.; Öllinger, K. Regulation of apoptosis-associated lysosomal membrane permeabilization. Apoptosis 2010, 15, 527-540.
30. Boya, P.; Kroemer, G. Lysosomal membrane permeabilization in cell death. Oncogene 2008, 27, 6434-6451.
31. Chen, W.; Li, N.; Chen, T.; Han, Y.; Li, C.; Wang, Y.; He, W.; Zhang, L.; Wan, T.; Cao, X. The lysosome-associated apoptosis-inducing protein containing the pleckstrin homology (PH) and FYVE domains (LAPF), representative of a novel family of PH and FYVE domain-containing proteins, induces caspase-independent apoptosis via the lysosomal-mitochondrial pathway. J. Biol. Chem. 2005, 280, 40985-40995.
32. Igney, F.H.; Krammer, P.H. Death and anti-death: Tumour resistance to apoptosis. Nat. Rev. Cancer 2002, 2, 277-288.
33. Ghavami, S.; Hashemi, M.; Ande, S.; Yeganeh, B.; Xiao, W.; Eshraghi, M.; Bus, C.; Kadkhoda, K.; Wiechec, E.; Halayko, A.; et al. Apoptosis and cancer: Mutations within caspase genes. J. Med. Genet. 2009, 46, 497-510.
34. Jager, U.; Bocskor, S.; Le, T.; Mitterbauer, G.; Bolz, I.; Chott, A.; Kneba, M.; Mannhalter, C.; Nadel, B. Follicular lymphomas' BCL-2/IgH junctions contain templated nucleotide insertions: Novel insights into the mechanism of t(14;18) translocation. Blood 2000, 95, 3520-3529.
35. Adachi, M.; Tefferi, A.; Greipp, P.R.; Kipps, T.J.; Tsujimoto, Y. Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia. J. Exp. Med. 1990, 171, 559-564.
36. Iqbal, J.; Sanger, W.G.; Horsman, D.E.; Rosenwald, A.; Pickering, D.L.; Dave, B.; Dave, S.; Xiao, L.; Cao, K.; Zhu, Q.; et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am. J. Pathol. 2004, 165, 159-166.
37. Roulland, S.; Navarro, J.-M.; Grenot, P.; Milili, M.; Agopian, J.; Montpellier, B.; Gauduchon, P.; Lebailly, P.; Schiff, C.; Nadel, B. Follicular lymphoma-like B cells in healthy individuals: A novel intermediate step in early lymphomagenesis. J. Exp. Med. 2006, 203, 2425-2431.
38. Rampino, N.; Yamamoto, H.; Ionov, Y.; Li, Y.; Sawai, H.; Reed, J.C.; Perucho, M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997, 275, 967-969.
39. Lee, J.W.; Soung, Y.H.; Kim, S.Y.; Nam, S.W.; Kim, C.J.; Cho, Y.G.; Lee, J.H.; Kim, H.S.; Park, W.S.; Kim, S.H.; et al. Inactivating mutations of proapoptotic Bad gene in human colon cancers. Carcinogenesis 2004, 25, 1371-1376.
40. Ambrosini, G.; Adida, C.; Altieri, D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997, 3, 917-921.
41. Mesri, M.; Wall, N.R.; Li, J.; Kim, R.W.; Altieri, D.C. Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Investig. 2001, 108, 981-990.
42. Byun, D.-S.; Cho, K.; Ryu, B.-K.; Lee, M.-G.; Kang, M.-J.; Kim, H.-R.; Chi, S.-G. Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res. 2003, 63, 7068-7075.
43. Yang, D.; Welm, A.; Bishop, J.M. Cell division and cell survival in the absence of survivin. Proc. Natl. Acad. Sci. USA 2004, 101, 15100-15105.
44. Annunziata, C.M.; Davis, R.E.; Demchenko, Y.; Bellamy, W.; Gabrea, A.; Zhan, F.; Lenz, G.; Hanamura, I.; Wright, G.; Xiao, W.; et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007, 12, 115-130.
45. Keats, J.J.; Fonseca, R.; Chesi, M.; Schop, R.; Baker, A.; Chng, W.-J.; van Wier, S.; Tiedemann, R.; Shi, C.-X.; Sebag, M.; et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 2007, 12, 131-144.
46. Bernal-Mizrachi, L.; Lovly, C.M.; Ratner, L. The role of NF-κB-1 and NF-κB-2-mediated resistance to apoptosis in lymphomas. Proc. Natl. Acad. Sci. USA 2006, 103, 9220-9225.
47. Lawrence, M.S.; Stojanov, P.; Mermel, C.H.; Robinson, J.T.; Garraway, L.A.; Golub, T.R.; Meyerson, M.; Gabriel, S.B.; Lander, E.S.; Getz, G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014, 505, 495-501.
48. Debatin, K.-M.; Krammer, P.H. Death receptors in chemotherapy and cancer. Oncogene 2004, 23, 2950-2966.
49. Özören, N.; El-Deiry, W.S. Cell surface death receptor signaling in normal and cancer cells. Semin. Cancer Biol. 2003, 13, 135-147.
50. Oltersdorf, T.; Elmore, S.W.; Shoemaker, A.R.; Armstrong, R.C.; Augeri, D.J.; Belli, B.A.; Bruncko, M.; Deckwerth, T.L.; Dinges, J.; Hajduk, P.J.; et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435, 677-681.
51. Tse, C.; Shoemaker, A.R.; Adickes, J.; Anderson, M.G.; Chen, J.; Jin, S.; Johnson, E.F.; Marsh, K.C.; Mitten, M.J.; Nimmer, P.; et al. ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor. Cancer Res. 2008, 68, 3421-3428.
52. Mérino, D.; Khaw, S.L.; Glaser, S.P.; Anderson, D.J.; Belmont, L.D.; Wong, C.; Yue, P.; Robati, M.; Phipson, B.; Fairlie, W.D.; et al. Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 2012, 119, 5807-5816.
53. Roberts, A.W.; Seymour, J.F.; Brown, J.R.; Wierda, W.G.; Kipps, T.J.; Khaw, S.L.; Carney, D.A.; He, S.Z.; Huang, D.C.S.; Xiong, H.; et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 2012, 30, 488-496.
54. Tan, N.; Malek, M.; Zha, J.; Yue, P.; Kassees, R.; Berry, L.; Fairbrother, W.J.; Sampath, D.; Belmont, L.D. Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models. Clin. Cancer Res. 2011, 17, 1394-1404.
55. Cragg, M.S.; Harris, C.; Strasser, A.; Scott, C.L. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat. Rev. Cancer 2009, 9, 321-326.
56. Souers, A.J.; Leverson, J.D.; Boghaert, E.R.; Ackler, S.L.; Catron, N.D.; Chen, J.; Dayton, B.D.; Ding, H.; Enschede, S.H.; Fairbrother, W.J.; et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 2013, 19, 202-208.
57. Vandenberg, C.J.; Cory, S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013, 121, 2285-2288.
58. Vaillant, F.; Merino, D.; Lee, L.; Breslin, K.; Pal, B.; Ritchie Matthew, E.; Smyth Gordon, K.; Christie, M.; Phillipson Louisa, J.; Burns Christopher, J.; et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell 2013, 24, 120-129.
59. Touzeau, C.; Dousset, C.; le Gouill, S.; Sampath, D.; Leverson, J.D.; Souers, A.J.; Maiga, S.; Bene, M.C.; Moreau, P.; Pellat-Deceunynck, C.; et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia 2014, 28, 210-212.
60. Tam, C.C.S.; Seymour, J.F.; Bell, A.; Westerman, D.A.; Juneja, S.; Huang, D.C.S.; Roberts, A.W. Selective Bcl-2 inhibition with ABT-199 is highly active against chronic lymphocytic leukemia (CLL) irrespective of TP53 mutation or dysfunction. Blood 2013, 122, 1304-1304.
61. Czabotar, P.E.; Lessene, G.; Strasser, A.; Adams, J.M. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 2014, 15, 49-63.
62. Mannhold, R.; Fulda, S.; Carosati, E. IAP antagonists: Promising candidates for cancer therapy. Drug Discov. Today 2010, 15, 210-219.
63. Chauhan, D.; Neri, P.; Velankar, M.; Podar, K.; Hideshima, T.; Fulciniti, M.; Tassone, P.; Raje, N.; Mitsiades, C.; Mitsiades, N.; et al. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood 2007, 109, 1220-1227.
64. Weisberg, E.; Kung, A.L.; Wright, R.D.; Moreno, D.; Catley, L.; Ray, A.; Zawel, L.; Tran, M.; Cools, J.; Gilliland, G.; et al. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Mol. Cancer Ther. 2007, 6, 1951-1961.
65. Steinhart, L.; Belz, K.; Fulda, S. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis. Cell Death Dis. 2013, 4, doi:10.1038/cddis.2013.320.
66. Belz, K.; Schoeneberger, H.; Wehner, S.; Weigert, A.; Bonig, H.; Klingebiel, T.; Fichtner, I.; Fulda, S. Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly. Blood 2014, 124, 240-250.
67. Yang, J.; McEachern, D.; Li, W.; Davis, M.A.; Li, H.; Morgan, M.A.; Bai, L.; Sebolt, J.T.; Sun, H.; Lawrence, T.S.; et al. Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases. Mol. Cancer Ther. 2011, 10, 658-669.
68. Zhang, S.; Li, G.; Zhao, Y.; Liu, G.; Wang, Y.; Ma, X.; Li, D.; Wu, Y.; Lu, J. Smac mimetic SM-164 potentiates APO2L/TRAIL- and doxorubicin-mediated anticancer activity in human hepatocellular carcinoma cells. PLoS One 2012, 7, e51461.
69. Ramachandiran, S.; Cain, J.; Liao, A.; He, Y.; Guo, X.; Boise, L.H.; Fu, H.; Ratner, L.; Khoury, H.J.; Bernal-Mizrachi, L. The Smac mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac. Leuk. Res. 2012, 36, 784-790.
70. Sheng, R.; Sun, H.; Liu, L.; Lu, J.; McEachern, D.; Wang, G.; Wen, J.; Min, P.; Du, Z.; Lu, H.; et al. A potent bivalent Smac mimetic (SM-1200) achieving rapid, complete, and durable tumor regression in mice. J. Med. Chem. 2013, 56, 3969-3979.